A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet experts say the results provide important direction for future drug development.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/failed-semaglutide-early-alzheimers-not-end-road-2025a1000y4l?src=rss
Author :
Publish date : 2025-12-05 13:04:00
Copyright for syndicated content belongs to the linked Source.